Sally Satel on Organ Donation

Episode Summary

Executive Summary: Russ Roberts and psychiatrist Sally Satel discuss her personal experience receiving two kidney transplants, the severe shortage of donor organs, and why she advocates incentives such as refundable tax credits to expand supply. They examine opposition from bioethicists and kidney groups, the ethics of compensation, black markets, and future technologies that may eventually eliminate the shortage.

Main Topics: Sally Satel’s personal transplant story (Priority: 5/5): Satel recounts unexpectedly learning she had kidney failure, struggling to find a donor, receiving a kidney from Virginia Postrel, and later needing a second transplant from Kim Hendrickson. The kidney shortage and dialysis as a fallback (Priority: 5/5): The conversation explains why kidney failure requires either a transplant or dialysis, how limited organ supply leads to long waits and deaths, and why the current system is inadequate. Directed donation, altruism, and legality (Priority: 5/5): Roberts and Satel distinguish directed donation to a specific person from donation to the general waiting list, and note that current law bans direct payment for organs while allowing altruistic gifts. Tax credits and other incentive proposals (Priority: 5/5): Satel outlines a pragmatic policy design using third-party-administered rewards, such as refundable tax credits, to encourage donation while preventing immediate cash-for-organ transactions. Ethical objections: commodification, coercion, exploitation (Priority: 4/5): They debate objections from the National Kidney Foundation, transplant professionals, and bioethicists, especially concerns that compensation would commodify body parts or crowd out altruism. Future solutions: synthetic organs and biotechnology (Priority: 3/5): Satel predicts that 3D-printed organs, transgenic pigs, implantable micro-dialysis systems, and other biomedical advances may eventually resolve the shortage.

Key Arguments: Living donation can transform or save lives, but the current altruism-only system leaves many patients waiting and some dying before a kidney becomes available. A directed donor should be allowed to give a kidney to a specific person of their choosing, because autonomy matters and the donor can simply refuse if they do not wish to proceed. Immediate cash payments raise worries about desperation and regret, so incentive proposals should use delayed, structured benefits like tax credits, loan forgiveness, or retirement contributions. The ban on compensation creates a black market and prevents transparent, safer exchanges that could both protect donors and increase supply. Opponents argue compensation commodifies the body and could reduce altruistic donation, but Satel and Roberts note those claims are partly testable and may be overstated. The transplant system already involves substantial money for surgeons and procurement organizations, so refusing to compensate donors while paying intermediaries is ethically inconsistent. Even if incentives are controversial, they may be justified because they could save many more lives and reduce reliance on dialysis, which is costly and burdensome. Long-term, biotechnology may solve the organ shortage, but policy changes are needed now because thousands die while waiting.

Data Points: Kidney transplants per year: 18,000 - Total kidney transplants in the U.S. mentioned during the discussion Living-donor kidney transplants: 5,600 - Approximate number of kidney transplants coming from living donors People on the kidney waiting list: 98,000 - Size of the transplant waiting list cited by Satel Annual deaths due to transplant shortages: 12 people per day - Satel’s estimate of daily deaths because a kidney was unavailable Dialysis cost per patient per year: $90,000 - Approximate Medicare spending on dialysis for one patient annually Dialysis share of Medicare budget: 7% - Portion of total Medicare spending devoted to dialysis Proposed reward value: $50,000 - Commonly cited intuitive value for a donor incentive in the policy discussion Proposed tax credit amount: $5,000 per year - Satel’s refundable tax credit design Tax credit duration: 10 years - If fully funded, the credit would be paid over a decade Alternative tax credit timing: $25,000 after five years - If the donor pays taxes, Satel described a faster payout structure Living kidney longevity: 15 to 20 years - Expected lifespan of a kidney from a living donor Cadaver kidney longevity: 10 to 12 years - Expected lifespan of a kidney from a deceased donor Immunosuppression withdrawal failure window: 2 to 4 weeks - Time after stopping anti-rejection drugs when an organ can begin failing Typical hospitalization after transplant: 5 to 6 days - Satel described her post-surgery stay Post-transplant infection restriction period: about 6 months - Time she was advised to avoid crowds, planes, and trains because of immunosuppression Transplant surgeons supportive of testing incentives: 75% - A 2009 poll of transplant surgeons found majority support for studying incentive proposals People who die annually waiting for organs: 7,000 to 8,000 - Estimated deaths from inability to survive the wait for an organ

Pivotal Quotes: "It was sort of a surprise. I just went to the doctor for a regular checkup, and this is the part of the story that scares everyone, because I felt completely fine." — Sally Satel: Describing the unexpected discovery of her kidney failure "The ban against rewarding people who would like to save someone's life." — Sally Satel: Summarizing the legal barrier she wants changed "The one person who takes the risk and gives the thing of value gets nothing." — Russ Roberts: Critiquing the current incentive structure for kidney donation

Implications: The episode argues that current organ policy costs lives and that carefully designed incentives could expand donation without fully commercializing organs. If biotech lags, reform may be the fastest path to fewer deaths and less dialysis dependence.